DNA methylation of microRNA genes in multiple myeloma by Wong, KY et al.
Title DNA methylation of microRNA genes in multiple myeloma
Author(s) Wong, KY; Huang, X; Chim, CS
Citation Carcinogenesis, 2012, v. 33 n. 9, p. 1629-1638
Issued Date 2012
URL http://hdl.handle.net/10722/152732
Rights
This is a pre-copy-editing, author-produced PDF of an article
accepted for publication in Carcinogenesis following peer
review. The definitive publisher-authenticated version
Carcinogenesis, 2012, v. 33 n. 9, p. 1629-1638 is available online
at: http://carcin.oxfordjournals.org/content/33/9/1629
1 
DNA methylation of microRNA genes in multiple myeloma 
Kwan Yeung WONG1, Xiaojun HUANG2, Chor Sang CHIM1* 
1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, 
China; 2Department of Hematology, Peking University Institute of Hematology, Beijing, 
China. 
*Corresponding Author: Dr CS Chim : 
Tel: +852 22553879; Fax: +852 28162187; Email: jcschim@hku.hk 
Keywords: multiple myeloma; methylation; tumor suppressor; miRNA; miR-34; miR-124; 
miR-194; miR-203 
2 
Abstract 
DNA methylation is one of the heritable epigenetic modifications, leading to repressed gene 
expressions and consequent phenotypic alterations without changing the DNA sequence. 
MicroRNA (miRNA) is a novel class of short non-coding RNA molecules regulating a wide 
range of cellular functions through translational repression of their target genes. Recently, 
epigenetic dysregulation of tumor suppressor miRNA genes by promoter DNA methylation 
has been implicated in human cancers, including multiple myeloma (MM). This article 
presents a brief overview of the pathogenesis of MM, the role of DNA methylation in cancer 
biology, methods of DNA methylation analysis, miRNA biology, dysregulation of miRNAs in 
MM, and summaries the current data on the role of DNA methylation of tumor suppressive 
miRNAs in MM. 
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Multiple myeloma 
 Multiple myeloma (MM) is a cancer arising from neoplastic proliferation of plasma cells. 
In the US, it is the second most common form of hematological malignancies, which 
accounts for approximately 15% of all hematological malignancies or approximately 1% of all 
malignant diseases [1]. Interestingly, the incidence of MM appears to be higher in Western 
than Asian countries [2]. 
 
Clinical stages of MM 
 The disease starts with immortalization of a post-germinal center B cell, which will then 
home to the bone marrow and clinically present as asymptomatic monoclonal gammopathy 
of undetermined significance (MGUS) (Figure 1). MGUS progresses to symptomatic MM at a 
rate of 1% per year, and hence is considered as the precursor of MM [3]. Symptomatic MM 
is characterized by the presence of end-organ damages which include hypercalcemia, renal 
failure, anemia, and bone lesions (CRAB) [4]. About 15% of all newly diagnosed MM patients 
are preceded by an additional intermediate stage, known as smoldering MM (SMM), which 
will evolve into symptomatic MM at a higher rate of 10% per year [5]. At the terminal stage, 
MM cells become independent of the bone marrow stroma, and hence extramedullary MM, 
such as plasma cell leukemia, may occur [6]. 
 
Molecular genetics of MM 
 Based on gene expression profiling, universal upregulation of D-type cyclins (cyclin D1, 
D2, or D3) is a hallmark of all MM [7]. However, MM remains a highly heterogeneous 
disease with variable losses and gains of chromosomes, and can be categorized into 
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non-hyperdiploid and hyperdiploid MM [8-10] (Figure 1). It has also been found that this 
ploidy dichotomy can also be detected even in MGUS, the precursor of symptomatic MM, 
and hence an early event of myelomagenesis [10,11]. 
 
 Non-hyperdiploid MM, constituting approximately half of all MGUS and MM, can be 
further subdivided into 3 categories, known as hypodiploid (chromosome number up to 
44/45; and/or DNA index less than 0.95), pseudodiploid (chromosome number between 
44/45 to 46/47; and/or DNA index between 0.95 to 1.05) and near-tetraploid (chromosome 
number greater than 75; and/or DNA index greater than 1.75). Majority of the 
non-hyperdiploid MM is associated with a primary translocation which involves juxtaposition 
of a strong immunoglobulin heavy chain gene enhancer locus to a partner oncogene 
important for myelomagenesis [12,13]. In MM patients, approximately 15% of patients 
harbor t(11;14)(q13;q32), which is associated with upregulation of oncogenic cyclin D1 
(CCND1) [13]. Another 15% of patients carry t(4;14)(p16.3;q32), which involves 
dysregulation of fibroblast growth factor receptor 3 (FGFR3) and wolf-hirschhorn syndrome 
candidate 1 (also known as MM SET domain, MMSET) [14,15]. Less frequent but 
distinguishable primary translocations, known as t(14;16)(q32;q23), t(6;14)(p21;q32) and 
t(14;20)(q32;q11), are found in approximately 5%, 3% and 2% of patients, leading to 
dysregulation of v-maf musculpaponeurotic fibrosarcoma oncogene homolog (avian) (MAF) 
(also known as c-MAF), cyclin D3 (CCND3) and v-maf musculpaponeurotic fibrosarcoma 
oncogene homolog B (avian) respectively [16-19]. 
 
 In contrast to the non-hyperdiploid MM, hyperdiploid MM constitutes another half of 
all MGUS and MM, due to trisomies of odd-numbered chromosomes including 3, 5, 7, 9, 11, 
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15, 19 or 21, resulting in a chromosome number between 46/47 to 75, as measured by 
conventional karyotyping; and/or a DNA index between 1.05 to 1.75. In contrast to other 
odd-numbered chromosomes frequently involved in hyperdiplody, chromosome 13 is often 
deleted instead [20,21]. Moreover, trisomy of chromosome 11, to which CCND1 is localized, 
has been shown to result in direct upregulation of CCND1 [22,23]. While the underlying 
mechanism leading to the aforementioned dichotomy of MM remains to be elucidated, it is 
noteworthy that, clinically, hyperdiploid MM patients are associated with better prognosis 
and treatment outcomes than the non-hyperdiploid MM patients [24-26]. 
 
 During disease progression, secondary translocations and other genetic aberrations, 
including deletion of the short arm of chromosome 17 [del(17p)] and mutations of RAS 
genes, etc, are involved [27]. Unlike primary translocations, which involve juxtaposition of 
the strong immunoglobulin heavy chain gene enhancer locus to a partner oncogene, the 
mechanisms of secondary translocations are less well-defined but appears unrelated to the 
error-prone B cell-specific DNA modification events. For instance, at the time of disease 
progression, about 15% of MM patients carry secondary immunoglobulin heavy chain 
translocation involving v-myc myelocytomatosis viral oncogene homolog (avian) (c-MYC) 
(8q24), which confers proliferative advantage to MM cells [27,28]. 
 
 Based on fluorescence in situ hybridization (FISH) analysis, del(13) is detected in 20% to 
50% of MGUS, and approximately 50% of MM. Notably, 90% of del(13) is characterized by 
monosomy 13, and interstitial deletion of 13q14 occurs in the remaining 10% of cases 
[20,21]. Despite that del(13) was once believed to impart poor prognosis, recently, the 
6 
prognostic impact of del(13) has been shown to be mediated by its strong association with 
unfavorable risk factor of t(4;14) [29,30]. 
 
 By interphase FISH analysis, del(17p), which is the locus for tumor suppressor protein 
TP53, is generally found in less than 10% of MM patients at diagnosis. However, presence of 
del(17p) at diagnosis is a powerful negative prognostic factor for MM [31,32]. A recent study 
of MM patients uniformly receiving bortezomib-based induction therapy prior to autologous 
stem cell transplantation further confirmed that del(17p) is associated with an inferior 
event-free survival (median time: 14 vs. 36 months) and overall survival (4-year OS: 50% vs. 
79%) as compared with those without del(17p). Therefore, the adverse impact of del(17p) 
appears not abolished by the use of targeted therapy [33]. 
 
 RAS mutations, predominantly K- and N-RAS at codon 12, 13 and 61, but not H-RAS, is 
present in more than half of MM at diagnosis but not in MGUS, suggesting that the RAS 
mutations is at least a marker of the transition from MGUS to MM [34-37]. 
 
 Last but not least, the bone marrow microenvironment is very important in the 
pathogenesis of MM for homing of MM plasma cell to the bone marrow and secretion of 
growth-stimulating cytokines to the MM plasma cells. The homing of MM plasma cell is a 
chemotaxis mechanism mediated by the bone marrow stromal cells secreted chemokine 
(C-X-C motif) ligand 12 or stromal cell-derived factor 1, which binds to its specific receptor, 
chemokine (C-X-C motif) receptor 4, expressed on the MM plasma cell. Moreover, upon 
cell-to-cell interactions between the bone marrow stromal cells and the MM plasma cells, a 
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multitude of cytokines are secreted, and hence favor the proliferation and survival of MM 
plasma cells by autocrine and paracrine signaling [e.g. interleukin 6 (IL6), insulin-like growth 
factor 1, tumor necrosis factor alpha and nuclear factor of kappa light polypeptide gene 
enhancer in B-cells (NFκB)], angiogenesis [e.g. vascular endothelial growth factor and basic 
fibroblast growth factor] and osteolysis [e.g. tumor necrosis factor (ligand) superfamily, 
member 11, tumor necrosis factor receptor superfamily, member 11a and tumor necrosis 
factor receptor superfamily, member 11b] [27,38,39]. 
 
DNA methylation 
DNA methylation and cancer 
 DNA methylation refers to catalytic addition of a methyl group (-CH) to carbon 5 
position of a cytosine ring in a CpG dinucleotide [40-44]. CpG dinucleotide cluster in any 
genomic region of over 200 bp in length with a high GC content of more than 50% and 
observed/expected CpG ratio larger than 0.60 is known as a CpG island [45,46]. In human, 
CpG island is associated with at least 50% of gene promoters. Methylation of a 
promoter-associated CpG island will lead to recruitment of histone methyltransferase, 
methyl-CpG-binding domain (MBD) protein and histone deacetylase, resulting in formation 
of a compact heterchromatin configuration, which precludes the binding of transcription 
factor complex, and hence silencing of the associated gene [46,47].  
 
 In normal cells, a majority of genes with promoter-associated CpG islands are usually 
unmethylated, associated with a euchromatin configuration, and hence are generally 
transcriptionally ready or active (Figure 2). However, a fraction of genes with 
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promoter-associated CpG islands are methylated, and hence silenced in normal cells 
including genetic imprinting and X-chromosome inactivation [48,49]. 
 
 On the other hand, in cancer cells, genes with promoter-associated CpG islands are 
aberrantly methylated in a tumor-specific manner, leading to gene silencing. In particular, 
hypermethylation of promoter-associated CpG islands of tumor suppressor genes, resulting 
in decreased or loss of gene expressions, and hence loss of tumor suppressor functions, has 
been implicated in carcinogenesis [40,41,43,44,50-52] (Figure 2). Furthermore, in cancers, 
hypermethylation of the tumor suppressor genes may serve as a second hit, in addition to 
deletion or mutation of the other allele, thereby fulfilling the Knudson’s two-hit hypothesis 
[53]. 
 
 In MM, by genome-wide or gene-specific approaches, aberrant DNA methylation has 
been found to mediate the loss of a number of protein-coding tumor suppressor genes 
regulating cell cycle progression, cell signaling or apoptosis, including cyclin-dependent 
kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase inhibitor 2B (CDKN2B), 
death-associated protein kinase, secreted frizzled-related protein 2 and suppressor of 
cytokine signaling 1 (SOCS1), etc [54,55]. 
 
Methods of DNA methylation analysis 
 Over the years, techniques of DNA methylation analysis have evolved from qualitative 
to quantitative in fashion, and from locus-specific to genome-wide in scale [56-58] (Table 1). 
Bisulfite conversion, which chemically deaminates or modifies unmethylated cytosine to 
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uracil, and hence translating an epigenetic variation (methylated or unmethylated) into a 
genetic difference (C or U), is an important procedure fundamental to most of the later 
methods [59,60]. 
 
(I) Candidate gene-specific methods 
 Before the integration of bisulfite conversion into DNA methylation research, earlier 
techniques mostly depend on enzymatic digestion and high-performance liquid 
chromatography (HPLC). For the methylation-sensitive restriction enzyme-based analysis, for 
example, DNA methylation pattern of CpG dinucleotides embedded in a CCGG sequence can 
be detected by the use of isoschizomer pair of HpaII and MspI, by which methylated CCGG 
can be digested by MspI but not by HpaII, together with gel electrophoresis and Southern 
blotting [61]. However, the use of restriction enzyme digestion is limited by the requirement 
of large amount of DNA and the availability of restriction enzyme cut site at the 
locus-of-interest. Moreover, it is less informative about the methylation pattern over a 
stretch of CpG dinucleotides and prone to generate false-positive results due to incomplete 
digestion. In addition to enzymatic digestion, HPLC was also employed in DNA methylation 
analysis in the early days [62]. However, the use of HPLC is also limited by the requirement 
of large amount of DNA and the need of skillful and tedious operation. 
 
 Later, Frommer et al. first incorporated bisulfite conversion into DNA methylation 
research, leading to the advent of bisulfite genomic sequencing (BGS), and subsequently a 
qualitative method, known as methylation-specific PCR (MSP). Moreover, bisulfite 
conversion is integrated to a number of quantitative methods, namely, combined bisulfite 
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restriction analysis (COBRA), methylation-sensitive single nucleotide primer extension 
(Ms-SNuPE), MethyLight, pyrosequencing and MassARRAY. 
 
 BGS generates the highest resolution map of the DNA methylation status of every 
single cytosine residue within a locus-of-interest, by the use of simple techniques including 
bisulfite conversion, PCR, cloning and sequencing [63]. Bisulfite-converted DNA is first 
amplified by primers, which do not span any CpG site and hence allow unbiased 
amplification of both methylated and unmethylated alleles. The amplicons are then cloned 
and sequenced. However, it is labor-intensive and hence is limited to small number of 
locus-of-interest and samples. 
 
 MSP is currently the most popular technique used in studying DNA methylation of 
locus-specific CpG sites because of its specificity and simplicity [64]. DNA methylation status 
of any given CpG site is revealed by PCR amplification of bisulfite-converted DNA with two 
sets of PCR primers, one specific to the methylated sequence and the other to the 
unmethylated sequence. With validated specific primers and PCR conditions, the 
methylation status in a large number of samples can easily be obtained. However, it is not a 
quantitative method. 
 
 COBRA is highly similar to one of the two classic methods for the use of restriction 
enzyme, however, with the incorporation of bisulfite conversion, it becomes a 
high-throughput and quantitative technique [65]. Upon bisulfite conversion, unmethylated 
BstUI recognition sites CGCG will be converted to TGTG, whereas methylated BstUI sites 
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remain unchanged. Followed by BstUI digestion and gel electrophoresis, methylation of a 
locus-of-interest can be quantified by [100% X intensity of (digested fragments/ both 
digested and undigested fragments)]. 
 
 Ms-SNuPE is a quantitative DNA methylation analysis method derived from primer 
extension technique [66]. In brief, primer extension is performed on bisulfite-treated 
locus-of-interest with 32P-labeled dCTP or dTTP, which enable differentiation and 
quantification of the methylated or unmethylated template. However, the use of radioactive 
isotopes hinders the popularity of this technique. 
 
 MethyLight, also known as quantitative MSP, enables simultaneous detection and 
quantification of bisulfite-treated methylated and unmethylated templates by two specific 
TaqMan probes labeled with different fluorophores [67]. By the use of real-time PCR, 
MethyLight is regarded as a high-throughput, sensitive and quantitative method in DNA 
methylation research. 
 
 Pyrosequencing, which originally designed to study single-nucleotide polymorphism by 
indirect detection of pyrophosphate (PPi) released during DNA synthesis, has also been 
applied to detect the C and T difference generated by bisulfite conversion [68,69]. During a 
primer extension process on a bisulfite-treated template, PPi is released in an equimolar 
fashion according to the number of incorporated nucleotides, resulting in a proportional 
conversion of PPi to ATP by sulfurylase, and hence a quantifiable firefly luciferase signal 
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driven by the ATP. However, such a high-throughput, accurate and quantitative method is 
limited by the length of individual read, which is only about 60 to 100 bp. 
 
 MassARRAY, a technique involving a combination of bisulfite conversion, in vitro 
transcription, RNA digestion and MALDI-TOF mass spectrometry, is another high-throughput 
quantitative DNA methylation analysis method [70]. In brief, bisulfite-treated 
locus-of-interest is amplified with an in vitro transcription tag, which allows later in vitro 
transcription. The transcripts will then be digested into fragments without affecting any of 
the original CpG sites. Based on mass difference arise from methylated (resulting G) and 
unmethylated (resulting A) on the fragments, quantification of the methylated or 
unmethylated fragment is enabled. However, this technology requires sophisticated 
operation. 
 
(II) Genome-wide methods 
 Recently, coupled with bisulfite conversion, methylation-sensitive restriction enzyme 
digestion or methylation-sensitive antibody purification, genome-wide analysis of DNA 
methylation is made possible with different kinds of DNA microarrays and high-throughput 
sequencing methods [57,71-73]. 
 
 Bisulfite-converted DNA, for instance, can be subjected to Infinium Methylation Assay 
(Illumina), which allows quantitative analysis of > 485,000 specific CpG dinucleotides per 
sample. By methylation-specific single-base primer extension, specific fluorescence-labeled 
nucleotides will be incorporated, and hence a ratio of different fluorescent signals indicating 
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the methylation status [74,75]. Other array platforms include Affymetrix, Agilent and 
NimbleGen. Alternatively, bisulfite-converted DNA libraries can be generated from 
sonication or restriction enzymes prior to high-throughput sequencing, resulting in 
whole-genome bisulfite sequencing (WGBS) or reduced representation bisulfite sequencing 
(RRBS), which is able to generate DNA methylome with single-base resolution [76,77]. 
 
 Moreover, methylation-sensitive restriction enzyme may be used to enrich methylated 
or unmethylated DNA for different kinds of tiling arrays and high-throughput sequencings. 
For instance, BstUI or HpaII digestion (cleaves unmethylated DNA) will lead to enrichment of 
methylated sequences, whereas MspI or McrBC digestion (cleaves methylated DNA) will 
result in enrichment of unmethylated sequences, which are followed by array or sequencing 
profiling [78,79]. 
 
 Alternatively, with the development of methylation-sensitive antibodies, such as 
MECP2 (methyl-CpG-binding protein 2), MBD1 and MBD2, which binds to methylated CpG 
sites, immunoprecipitation of methylated sequences prior to DNA microarrays or 
high-throughput sequencing is enabled and collectively known as MeDIP (methylated DNA 
immunoprecipitation)-chip, when it is analyzed by DNA microarray, or MeDIP-seq, when it is 
analyzed by high-throughput sequencing method [80,81]. 
 
MicroRNA (miRNA) 
History and biogenesis 
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 miRNA is a class of short non-coding RNA molecules of 20 to 30 nucleotides (nts) in 
length [82]. miRNAs inhibit the translation of their own target genes via binding of the 
miRNA seed region (i.e. the 2nd to 7th nts from 5’ to 3’ of the mature miRNA) to the three 
prime untranslated region (3’UTR) of the target gene, and hence involve in the regulation of 
various cellular activities, including development, differentiation, proliferation, and 
apoptosis [83-86] (Figure 3). 
 
 The first miRNA was identified in Caenorhabditis elegans, in which lin-4 miRNA was 
found controlling the gradual decrease of LIN-14 protein expression from developmental 
stage L1 to later larval stages, through binding to the 3’UTR of lin-14 messenger RNA (mRNA), 
leading to translational inhibition of the lin-14 mRNA [87,88]. Later, with more small 
non-coding RNAs discovered in C. elegans, this class of RNAs was collectively named as 
miRNAs by Thomas Tuschl, David Bartel, and Victor Ambros [89-91]. 
 
 Most miRNA genes are associated with RNA polymerase II promoter and are generally 
first transcribed into primary (pri-) miRNA (>100 nts) by RNA polymerase II in the nucleus 
[92]. A pri-miRNA transcript is first stabilized by 5’capping and 3’polyadenylation, and then 
further processed into precursor (pre-) miRNA by RNase III Drosha and its co-factor Pasha 
[93,94]. A pre-miRNA (60 to 80 nts) forms a hairpin or stem-loop structure, followed by 
export into the cytoplasm through Ran-GTP-dependent exportin 5 [95,96]. In the cytoplasm, 
the pre-miRNA is further processed by RNase III Dicer into mature miRNA duplex (22 to 25 
nts), which will then be loaded into a RNA-induced silencing complex (RISC) [94]. The 
functional mature miRNA strand of the duplex is retained in the RISC for recognizing the 
mRNA target through sequence complementarity between the miRNA seed region and the 
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3’UTR of the target gene. Subsequently, the target gene is inhibited by either translational 
inhibition or mRNA degradation mediated by the miRNA-associated RISC [97,98]. 
 
 Precise miRNA expression is essential for normal cellular functions, including apoptosis, 
proliferation, and differentiation [83-86]. Conversely, dysregulation of miRNA expression is 
implicated in various diseases, including cancers. 
 
miRNA, DNA methylation and Knudson’s hypothesis 
 Mechanistically, miRNAs play a role in the regulation of DNA methylation in cancers. 
miR-29 family miRNAs are downregulated in cancers including acute myeloid leukemia (AML) 
and non-small cell lung cancer [99,100]. Moreover, it has been shown that the miR-29 family 
miRNAs are tumor suppressive miRNAs targeting DNA methyltransferase (DNMT) 3A and 3B, 
which are responsible for initiation of de novo DNA methylation [101,102]. Indeed, 
restoration of the miR-29 family miRNAs in lung cancer cells led to inhibition of cellular 
proliferation, induction of apoptosis and reduced tumorigenicity in mice. Furthermore, by 
targeting DNMT3A and 3B, restoration of the miR-29 family miRNAs resulted in 
re-expression of hypermethylated tumor suppressor genes, including CDKN2B and estrogen 
receptor 1 in AML cells, and fragile histidine triad and WW domain containing 
oxidoreductase in lung cancer cells by gene hypomethylation. Therefore, miR-29 family 
miRNAs are involved in locus-specific hypermethylation of tumor suppressor genes via 
inhibition of DNMTs. 
In breast and cervical cancers, CDKN2A and SOCS1 are important tumor suppressor 
genes inactivated by DNA hypermethylation. [103,104]. On the other hand, miR-24 and 
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miR-155 are oncogenic miRNAs over-expressed in breast and cervical cancers [105,106]. 
Furthermore, miR-24 and miR-155 have been shown to target the 3’UTR of, and hence 
repress CDKN2A and SOCS1 respectively. [106,107]. Therefore, in addition to gene 
hypermethylation, tumor suppressor genes can be translationally repressed by oncogenic 
miRNAs, suggesting that the Knudson’s hypothesis can potentially be fulfilled by a complex 
co-operation of gene alterations with one allele inactivated by gene deletion, mutation or 
hypermethylation, and the other allele by miRNA targeting. 
Thus, these data suggested that miRNAs play multifaceted role in carcinogenesis. Later 
part of this article focuses on the role of DNA methylation of tumor suppressor miRNAs in 
MM. 
 
Dysregulation of miRNAs in MM 
 Dysregulation of miRNAs has been implicated in MM [108,109]. In brief, by miRNA 
expression profiling using hybridization or Taqman low-density array, miRNAs were found 
aberrantly expressed in MM cells as compared with their healthy counterparts [110-116]. 
Moreover, miRNA signatures were found associated with distinct genetic subtypes, such as 
t(4;14), t(11;14) and t(14;16), and different clinical stages of MM [110,112,114-117]. 
Furthermore, of these dysregulated miRNAs, some were found to be involved in the 
regulation of cell cycle, proliferation and apoptosis. For examples, miR-21 and miR-17-92 
were identified as oncogenic miRNAs, leading to enhanced survival and reduced apoptosis of 
MM [110,118]. In particular, upregulation of miR-21, a downstream target of activator of 
transcription 3 (STAT3), was found to potentiate the proliferative IL6-mediated signal 
transducer and STAT3 signaling in MM. In contrast, miR-15a and miR-16-1 were found to be 
tumor suppressor miRNAs, resulting in increase of apoptosis and suppression of NFκB 
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pathway in MM cells [111,119]. Moreover, these studies showed that some known tumor 
suppressor miRNAs, such as let-7, miR-29 and miR-193, are downregulated in MM. 
 
Downregulation of miRNA expression in cancers may be mediated by various 
mechanisms, ranging from epigenetic inactivation, gene mutation or copy number loss to 
defective miRNA biogenesis or post-transcriptional processing [120]. Of these, DNA 
methylation is associated with repression of miRNAs possessing promoter-associated CpG 
islands [121]. Furthermore, the expressions and functions of these tumor suppressor 
miRNAs can be reversed and restored by DNA hypomethylation treatment [122]. Therefore a 
better understanding of epigenetic inactivation of tumor suppressor miRNA genes is 
essential for the biology and treatment in human cancers including MM. Recently, the 
following studies described the role of DNA methylation of tumor suppressor miRNA genes, 
including miR-34a, miR-34b/c, miR-194-2-192, miR-203 and miR-124-1, in MM. 
 
Aberrant methylation of miRNA in MM 
miR-34a 
The tumor suppressor protein TP53 plays a central role in the tumor suppression 
network, in response to carcinogenic cellular stress and DNA damage, through the induction 
of apoptosis, cell cycle arrest and senescence [123]. Deletion of the short arm of 
chromosome 17, to which TP53 gene is localized, confers an adverse impact on event-free 
and overall survival of MM patients [29,124]. However, homozygous deletion or mutation of 
the TP53 gene is rarely found in MM patients [32,125]. Therefore, it was hypothesized that 
18 
the dysregulation of the TP53-mediated tumor suppression may be due to inactivation of 
other tumor suppressive components along the TP53 pathway in MM. 
 
Recently, the miR-34 gene family members (miR-34s), including miR-34a, miR-34b and 
miR-34c, have been shown to be direct transcriptional targets and tumor suppressive 
effectors downstream to the TP53 [126-131]. Deletion or mutation of the TP53 gene 
abrogates the miR-34s expression, leading to attenuated TP53-mediated tumor suppression 
activities, and hence loss of translational repression of the miR-34s target genes, such as 
B-cell CLL/lymphoma 2, CCND1, cyclin E2, cyclin-dependent kinase (CDK) 4, CDK6, E2F, v-myc 
myelocytomatosis viral related oncogene, neuroblastoma derived (avian) and sirtuin 1, etc 
[132-139]. 
 
With the presence of promoter-associated CpG island at each of the miR-34a (1p36) 
and miR-34b/c (11q23) promoters, frequent DNA hypermethylation of the miR-34s gene, 
leading to silencing of the miR-34s, and hence upregulation of the miR-34s target genes has 
been found in a wide range of solid cancers, including bladder, breast, colon, lung, 
melanoma, neuroblastoma, prostate, and ovarian cancer, etc [126,127,129,130,140-143]. 
 
In hematological cancers, Chim et al. studied the methylation status of the miR-34a in a 
broad spectrum of primary samples, consist of AML, chronic myeloid leukemia (CML), acute 
lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), MM, non-Hodgkin’s 
lymphoma (NHL) and Philadelphia chromosome negative (Ph-ve) myeloproliferative diseases 
(MDS) [144,145]. Both of these studies showed that the promoter-associated CpG island of 
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the miR-34a was unmethylated in normal controls but aberrantly methylated in 50% of the 
hematological cancer cell lines, including human myeloma cell lines (HMCLs). Treatment 
with 5-aza-2’-deoxycytidine led to demethylation of the miR-34a promoter and consequent 
re-expression of the pri-miR-34a transcript in cells homozygously methylated for the 
miR-34a. Among primary samples at diagnosis, the miR-34a promoter was preferentially 
methylated in 18.8% NHL (p=0.018), 5.5% MM, 4.0% CLL and 2.2% MDS and none of ALL, 
AML and CML. Furthermore, in MM, with paired primary samples of at diagnosis and at 
relapse/progression, it was also shown that methylation of the miR-34a promoter remained 
infrequent even at the time of disease relapse/progression. Therefore, in contrast to the 
frequent methylation of miR-34a in epithelial cancers [142,146], methylation of the miR-34a 
promoter appears unimportant in MM pathogenesis and progression. 
 
miR-34b/c 
In contrast to miR-34a, methylation of the miR-34b/c was implicated in the progression 
of MM [147]. In a recent study, the promoter-associated CpG island of the miR-34b/c was 
shown to be unmethylated in normal controls but aberrantly methylated in 75% of the 
HMCLs, in which the expression of mature miR-34b inversely correlated with the 
methylation status of the miR-34b/c promoter. Moreover, hypomethylation treatment with 
5-aza-2’-deoxycytidine led to demethylation of the miR-34b/c promoter and concomitant 
re-expression of the mature miR-34b in myeloma cells homozygously methylated for the 
miR-34b/c, thereby confirming miRNA silencing was associated with promoter 
hypermethylation. Furthermore, restoration of the miR-34b led to inhibition of cellular 
proliferation and concomitant increase of apoptosis in MM cells, thereby confirming the 
tumor suppressor role of the miR-34b in MM. In primary samples, hypermethylation of the 
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miR-34b/c promoter occurred in only 5.3% diagnostic MM but 52.2% relapsed MM samples 
(p<0.001). Moreover, in 12 MM patients with paired samples at both diagnosis and relapse, 
apart from one showing methylation of the miR-34b/c promoter at both diagnosis and 
relapse, hypermethylation of the miR-34b/c promoter was acquired at the time of relapse in 
six (54.5%) patients. Therefore, miR-34b/c promoter methylation is acquired at relapse, and 
hence a biomarker of disease progression in MM. 
 
Therefore, the frequent methylation of miR-34b/c in MM at relapse is consistent with 
the notion that inactivation of other components of the TP53 tumor suppression network 
may be involved in MM. 
 
miR-194-2-192 
In addition to the miR-34s, which mediates TP53-associated tumor suppression, 
Pichiorri et al. found that the expression of miR-194-2-192 (11p13.1) miRNA cluster was also 
TP53-dependent, and could be silenced by DNA hypermethylation in HMCLs [148]. First, they 
showed that the expression of the miR-194-2-192 cluster was higher in HMCLs with intact 
TP53 expression as compared with those with deleted or mutated TP53. Moreover, in cells 
with intact TP53, treatment with Nutlin-3a, a small-molecule inhibitor of Mdm2, TP53 E3 
ubiquitin protein ligase homolog (mouse), upregulated expression of TP53, and 
consequently miR-194-2-192 cluster in both HMCLs and primary MM plasma cells. However, 
the authors found that, upon treatment with Nutlin-3a, despite successful activation of the 
wild-type TP53, the miR-194-2-192 cluster was not uniformly re-expressed in all HMCLs and 
primary MM plasma cells. In search of the mechanism for this discordance, the authors 
showed that the promoter-associated CpG island of the miR-194-2-192 cluster was 
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hypermethylated, and hence, upon hypomethylation treatment, the miR-194-2-192 cluster 
could be re-expressed in HMCLs possessing intact TP53 expression. Moreover, the tumor 
suppressive property of the miR-194-2-192 cluster was demonstrated by, upon 
overexpression of the miR-194-2-192 cluster, the inhibition of cellular proliferation (by 
growth assays) and blockage of MM cell migration (by trans-well assay). The possible tumor 
suppressor role of the miR-194 was further illustrated in another study, in which high 
expression of the miR-194 was associated with superior overall survival in MM patients 
[116]. 
 
miR-203 
Epigenetic inactivation of the tumor suppressor miRNA miR-203, localized to 14q32, 
was reported in CML, hepatocellular carcinoma and a wide range of hematological 
malignancies [145,149-151]. While juxtaposition of the 14q32 immunoglobulin heavy chain 
enhancer to an oncogene partner occur in approximately 50% of MGUS and SMM, > 75% of 
MM, and > 80% of PCL, leading to upregulation of oncogenes, such as CCND1, CCND3, FGFR3, 
MMSET, and MAF [12,13], double-stranded DNA breaks inherent with the translocation may 
result in DNA loss [152], and hence potential loss of tumor suppressor gene or miRNA. Wong 
et al. hypothesized that hypermethylation of the promoter-associated CpG island, and hence 
silencing of miR-203 might contribute to the development of MM, by fulfilling the Knudson’s 
two-hit hypothesis [53]. Therefore, the authors studied the methylation status of miR-203 in 
HMCLs, together with primary samples from patients with MGUS, MM at diagnosis and MM 
at relapse/progression, by MSP [153]. This study showed that the promoter-associated CpG 
island of miR-203 was unmethylated in normal controls but homozygously methylated in 
25% of the HMCLs, in which hypomethylation treatment led to demethylation of the 
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miR-203 promoter and concomitant re-expression of the mature miR-203. Furthermore, 
based on the same search result yielded by both bioinformatics algorithms miRanda and 
TargetScan, the authors further validated cyclic AMP responsive element binding protein 1 
(CREB1) mRNA as a novel direct target of the miR-203, by luciferase assay. Upon 
overexpression of miR-203, the luciferase activity was reduced in cells transfected with 
constructs carrying wild-type CREB1 3’UTR but not in cells transfected with constructs 
carrying mutant CREB1 3’UTR, thereby confirming CREB1 as a target of miR-203. Moreover, 
restoration of miR-203 led to downregulation of CREB1 protein and inhibition of cellular 
proliferation of MM cells. In primary samples, hypermethylation of the miR-203 promoter 
occurred at similar frequency in MGUS, MM at diagnosis and 21% MM at 
relapse/progression (MGUS: 25%, MM at diagnosis: 24%, MM at relapse/progression: 21%; 
p=0.973). Therefore, miR-203 methylation may be an early event in the development of 
myelomagenesis. 
 
miR-124-1 
One of the first and most well-defined epigenetically silenced tumor suppressor 
miRNAs is miR-124-1. Hypermethylation of the miR-124-1 has been reported in majority of 
patients with ALL, brain, cervical, colon and liver cancers, leading to direct inhibition of CDK6 
translation by binding on the 3’ UTR of the CDK6 mRNA, thereby tumor suppressive 
[151,154-157]. Later, Wong et al. reported a study of the miR-124-1 methylation in different 
types of hematological malignancies, including MM [158]. The promoter-associated CpG 
island of the miR-124-1 was shown to be unmethylated in normal controls but frequently 
methylated in 75% of the HMCLs. Upon 5-aza-2’-deoxycytidine treatment of MM cells with 
homozygous methylation of miR-124-1, re-expression of the mature miR-124 was associated 
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with demethylation of the miR-124-1 promoter and a euchromatic trimethyl H3K4 histone 
code, leading to repression of CDK6 expression. In primary samples, surprisingly, 
hypermethylation of the miR-124-1 promoter was detected only in 2% primary MM samples 
at diagnosis or relapse/progression. Together, the authors reasoned that frequent 
methylation of the miR-124-1 promoter in human myeloma cell lines was a result of in vitro 
passaging, and hence unimportant in the pathogenesis of MM. 
 
Conclusion and future perspectives 
 Current data on DNA methylation of miRNAs in MM focuses on the loss of tumor 
suppressor miRNAs due to promoter DNA hypermethylation. Epigenetic inactivation of these 
tumor suppressor miRNAs is involved in the pathogenesis (miR-194-2-192 and miR-203) and 
progression (miR-34b/c) of MM. Hence, DNA methylation of miRNAs can potentially be 
biomarker for diagnosis or relapse in MM. Importantly, while deletion or inactivating TP53 
mutation is infrequent in MM, abrogation of the TP53 tumor suppression machinery can be 
achieved by inactivation of the TP53 transcriptional targets, such as the miR-34 family 
members and miR-194, by DNA methylation. 
 
Moreover, methylation of these tumor suppressor miRNAs can be reversed by 
hypomethylation treatment, leading to restoration of corresponding expression and tumor 
suppressor function of these miRNAs. Epigenetic therapy has recently emerged as a  
state-of-the-art strategy in cancer treatment [159,160]. For instance, pharmacological grade 
DNA methyltransferase inhibitors have been approved for the treatment of myelodysplastic 
syndrome [161]. Therefore, these findings on methylation of tumor suppressor miRNAs may 
provide a foundation for the use of epigenetic drugs in the treatment of MM. In addition, 
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these data also suggest the potential use of tumor suppressor miRNA mimics as a cancer 
therapy in tumors lacking certain critical tumor suppressor miRNAs [162]. 
 
 Last but not least, these data highlight the importance of methylation of tumor 
suppressor miRNAs in MM with respect to the disease pathogenesis, diagnosis and therapy. 
Therefore, future genome-wide analysis of DNA methylation of miRNAs in MM will allow 
identification of novel miRNAs important in myelomagenesis.
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Legends: 
Figure 1: Clinical stages and molecular genetics of multiple myeloma. CCND: cyclin D; 
CDKN2C: cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4); FGFR3: fibroblast growth 
factor receptor 3; HMCL: human myeloma cell line; MAF: v-maf musculoaponeurotic 
fibrosarcoma oncogene homology (avian); MAFB: v-maf musculoaponeurotic fibrosarcoma 
oncogene homology B (avian); MGUS: monoclonal gammopathy of undetermined 
significance; MMSET: Wolf-Hirschhorn syndrome candidate 1; NF-κB: nuclear factor of kappa 
light polypeptide gene enhancer in B-cells; PCL: plasma cell leukemia; SMM: smoldering 
multiple myeloma. Derived from Smadja et al., 2001; Kuehl et al., 2002; Debes-Marun et al., 
2003; Fonseca et al., 2003; Chng et al., 2006 [24-27,163]. 
 
Figure 2: Role of DNA methylation in normal and cancer cells. In normal cell, CpG 
dinucleotides (lollipops) of promoter-associated CpG island are generally unmethylated 
(blue lollipops) and is associated with a euchromatin histone configuration, which allows 
access of transcription factors (TFs), histone acetyltransferases (HATs), H3K4 histone 
methyltransferase (HMT), and RNA polymerase complex, for gene transcription. In cancer 
cell, promoter-associated CpG island are aberrantly hypermethylated (black lollipops) by 
DNA methyltransferase (DNMT), leading to recruitment of histone deacetylase (HDAC) and 
HMT, results in a heterochromatic histone configuration, and hence gene silencing. (Co-Act, 
co-activator; DNMT, DNA methyltransferase; HAT, histone acetyltransferase; HDAC, histone 
deacetylase; HMT, histone methyltransferase; MBD, methyl-CpG-binding domain protein; 
Pol II, RNA polymerase II; TAF, TBP-associated factor; TBP, TATA-binding protein; TF, 
transcription factor). Modified from Wong et al., 2011 [146]. 
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Figure 3: Mechanisms of miRNA biogenesis and function. Most miRNA genes are transcribed 
by RNA polymerase II (Pol II) into primary (pri-) miRNA, which is processed into precursor 
(pre-) miRNA stem-loop by Drosha and Pasha. Pre-miRNA is transported into cytoplasm via 
exportin 5, and is processed into mature miRNA duplex by Dicer. The functional strand, 
which recognizes target gene, is loaded into RNA-induced silencing complex (RISC). Partial 
complementary binding of the miRNA to the 3’ untranslated region of target gene through 
the miRNA seed region will result in translation inhibition of target gene. Perfect 
complementary binding of the miRNA will induce mRNA degradation of target gene. 
Extracted from PhD thesis of K.Y.W. [164] (ORF, open reading frame; Pol II, RNA polymerase 
II; RISC, RNA-induced silencing complex; UTR, untranslated region)  
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Table 1: Common DNA methylation analysis methods 
 Locus-specific  Genome-wide 
Qualitative MSP   
Quantitative BGS  Infinium 
 COBRA  WGBS 
 Ms-SNuPE  RRBS 
 MethyLight  Enzyme-chip 
 Pyrosequencing  Enzyme-seq 
 MassARRAY  MeDIP-chip 
   MeDIP-seq 
Keys: BGS, bisulfite genomic sequencing; chip, DNA microarray; COBRA, combined bisulfite 
restriction analysis; MeDIP, methylated DNA immunoprecipitation; MSP, 
methylation-specific polymerase chain reaction; Ms-SNuPE, methylation-sensitive single 
nucleotide primer extension; seq, high-throughput sequencing; RRBS, 
reduced representation bisulfite sequencing; WGBS, whole-genome bisulfite sequencing. 
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Table 2: List of tumor suppressor miRNAs hypermethylated in multiple myeloma 
miRNA Genomic 
location 
Key known 
target 
Hypermethylated in other 
cancer type 
Reference 
miR-34a 1p36 BCL2 
CDK4/6 
E2F3 
Prostate 
Ovary 
[140,142,144] 
miR-34b/c 11q23 CCNE2 
CREB 
MET 
Colon 
Ovary 
[131,147,165,1
66] 
miR-124-1 8p23 CDK6 Colon 
ALL 
[154,157,158] 
miR-194-2-192 11q13 MDM2 Nil [148] 
miR-203 14q32 BCR-ABL 
CREB 
CML 
 
[149,153] 
Keys: BCL2, B-cell CLL/lymphoma 2; BCR-ABL, breakpoint cluster region c-abl oncogene 1, 
non-receptor tyrosine kinase; CCNE2, cyclin E2; CDK4/6, ; CREB, cAMP responsive element 
binding protein; E2F3, E2F transcription factor 3; MET, met proto-oncogene; MDM2, Mdm2, 
TP53 E3 ubiquitin protein ligase homolog (mouse). 
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